Dana DiRenzo, MD, MHS
Dana DiRenzo, MD, MHS, instructor of medicine at Johns Hopkins, spoke with Healio about recently approved treatment options for rheumatoid arthritis, highlighting the role of JAK-inhibitors in RA management and factors that may increase an individual’s risk for RA. In this video, DiRenzo discusses:
- Recent FDA approvals of treatments for rheumatoid arthritis, including JAK-inhibitors such as upadacitinib (Rinvoq, AbbVie), tofacitinib (Xeljanz, Pfizer) and baricitinib (Olumiant, Eli Lilly);
- Her own clinical experience using new treatments in practice, noting that JAK-inhibitors most benefit patients with treatment refractory RA;
- Patients who would not benefit from treatment with interleukin 6 receptor inhibitors, and when drugs in this class are best used;
- Treatment recommendations for patients with early RA; and
- Important areas of research and clinical study that will impact the future of RA treatment and management.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.